Aktuellt
SENASTE
Redeye notes that Alzecure’s Q4 report presented revenues of SEK0m and net result of SEK-11m, which largely aligns with our expectations. We also conclude that there is continued strong pipeline in the company, and were were overall also impressed by the recent oversubscribed rights issue in the company. We expect an exciting 2023 and will soon return with a research update.
LÄS MER
